title: Overexpression of Hrad17 gene in non-small cell lung cancers correlated with lymph node metastasis.
abstract: We used palindromic PCR-driven cDNA differential display technique to identify and isolate a gene, human homologue of the Schizosaccharomyces pombe checkpoint gene rad17, from colon cancer tissues. The loss of checkpoint control in mammalian cells results in genomic instability, leading to the amplification, rearrangement, or loss of chromosomes, events associated with tumor progression. We hypothesized that the Hrad17 may be expressed in non-small cell lung cancer (NSCLC). We attempted to determine the influence of Hrad17 expression on clinicopathological features for patients with NSCLC who had undergone surgery. Expression of Hrad17 messenger RNA was evaluated by reverse transcription-polymerase chain reaction (RT-PCR) in 102 non-small cell lung carcinomas and adjacent histologically normal lung samples from patients for whom follow up data were available. Hrad17 transcripts were detected in 26 (25.5%) of the tumor samples, although some of the paired normal lung samples showed weak expression. There was no relationship between Hrad17 gene expression and age, gender or T-status. About 13 of 31 (41.9%) NSCLC patients with Hrad17 overexpressions were node positive, on the other hand, 13 of 76 (18.3%) cases without Hrad17 overexpressions were node positive. Thus the expression of Hrad17 mRNA correlated with lymph node metastasis (P=0.0231) from NSCLC. Hrad17 protein was highly expressed at the advancing margin of the tumor of lung cancer tissue but not within the normal lung tissue by immunohistochemistry. Thus the expression of Hrad17 might correlate with more advanced NSCLC.
authors.affiliation: Department of Surgery II, Nagoya City University Medical School, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, 467-8601, Japan. hisasaki@med.nagoya-u.ac.jp
authors.forename: H
authors.initials: H
authors.lastname: Sasaki
authors.forename: L B
authors.initials: LB
authors.lastname: Chen
authors.forename: D
authors.initials: D
authors.lastname: Auclair
authors.forename: S
authors.initials: S
authors.lastname: Moriyama
authors.forename: M
authors.initials: M
authors.lastname: Kaji
authors.forename: I
authors.initials: I
authors.lastname: Fukai
authors.forename: M
authors.initials: M
authors.lastname: Kiriyama
authors.forename: Y
authors.initials: Y
authors.lastname: Yamakawa
authors.forename: Y
authors.initials: Y
authors.lastname: Fujii
mesh_terms: D000328:Adult; D000368:Aged; D002289:Carcinoma, Non-Small-Cell Lung / Q000235:genetics* / Q000473:pathology* / Q000601:surgery; D018797:Cell Cycle Proteins / Q000032:analysis / Q000096:biosynthesis*; D018076:DNA, Complementary / Q000235:genetics; D018450:Disease Progression; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007150:Immunohistochemistry; D008175:Lung Neoplasms / Q000235:genetics* / Q000473:pathology* / Q000601:surgery; D008207:Lymphatic Metastasis / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012333:RNA, Messenger; D020133:Reverse Transcriptase Polymerase Chain Reaction
chemical_list: D018797:Cell Cycle Proteins; D018076:DNA, Complementary; D012333:RNA, Messenger; C113575:Rad17 protein, human